Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial

MLA

Seung Tae Kim, et al. “Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial.” Translational Oncology, vol. 12, no. 4, Apr. 2019, pp. 597–601. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....5231e8b01bf0d0450793ee8e4152fadf&authtype=sso&custid=ns315887.

APA

Seung Tae Kim, Su Jin Lee, Young Suk Park, Esha A. Gangolli, Kyoung-Mee Kim, Ho Yeong Lim, Se Hoon Park, Peter G. Mortimer, Joon Oh Park, Minhwa Park, Hyeong Chan Shin, Jeeyun Lee, Won Ki Kang, & Simon J. Hollingsworth. (2019). Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial. Translational Oncology, 12(4), 597–601.

Chicago

Seung Tae Kim, Su Jin Lee, Young Suk Park, Esha A. Gangolli, Kyoung-Mee Kim, Ho Yeong Lim, Se Hoon Park, et al. 2019. “Combination of Docetaxel Plus Savolitinib in Refractory Cancer Patients: A Report on Phase I Trial.” Translational Oncology 12 (4): 597–601. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....5231e8b01bf0d0450793ee8e4152fadf&authtype=sso&custid=ns315887.